Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Secale cereale allergen extract is an extract derived from the pollen of rye (Secale cereale). It is utilized for both the diagnosis of rye pollen allergy and for allergen-specific immunotherapy (AIT). For diagnostic purposes, the extract is administered via a skin prick test; a positive wheal-and-flare reaction in a sensitized individual confirms the presence of specific IgE antibodies. [18, 19, 25] As a therapeutic agent, progressively larger doses are given to the patient, typically through subcutaneous injection, to induce immunological tolerance and mitigate allergic symptoms upon environmental exposure to rye pollen. [18] LETI Pharma, the sponsor of the clinical trial referenced in the provided context, is a known developer of allergenic extracts for both diagnostic and therapeutic applications. [22, 23, 26]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on secale cereale allergen extract.